Clinical Trial Update: Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the effect of sapanisertib (MLN0128) on QTc interval in participants with advanced solid tumors; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Sapanisertib (sapanisertib)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2020-03-03